盟科藥業(688373.SH):計劃於上半年通過橋接康替唑胺片已有臨牀證據啟動康替唑胺磷酸鹽(MRX-4)的關鍵臨牀試驗
格隆匯5月25日丨有投資者向盟科藥業(688373.SH)提問:注射用MRX-4預計國內上市時間?
盟科藥業回覆:公司計劃於2023年上半年通過橋接康替唑胺片已有臨牀證據啟動康替唑胺磷酸鹽(MRX-4)的關鍵臨牀試驗,以支持在中國提交上市申請。公司已經就該臨牀試驗方案與國家藥監局藥品審評中心(CDE)完成了溝通交流並達成共識。公司預計在明年完成該臨牀試驗的入組工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.